Plant engineering technology has been working effectively since last 30 years. Commercialization of different product using plant engineering is encouraging us to develop effective treatment and this progress takes too much effort and time, but still many candidate vaccines for use in humans are in clinical trials. Virus-like particles (VLPs) are basically self-constructed structures departed from viral antigens which copy the organization of similar viruses but without viral genome. This technology offers several pros in terms of safety, immunogenicity and stability in production over vaccines derived from pathogen formulation. Now, many pharmaceutical companies are working in this technology to develop effective treatment against various diseases. This review discusses how plant engineering technology works for diseases and regulations relevant to the development of plant-based vaccines in the treatment of viruses like Hepatitis B, Ebola, Papilloma, Norwalk, Influenza, HIV and Covid-19. Keywords: Plant engineering technology, Virus-like Particles, Pathogens, Antibodies.